Jamjoom Pharma
جمجوم فارماTechnical Analysis & Signals
Jamjoom Pharma closed at SAR 119.2, up 1.79%. RSI at 48.5 in neutral zone. Current signal: Hold.
Technical Analysis
Jamjoom Pharma closed at SAR 119.2, below the 50-day SMA (125.17 SAR). RSI at 48.5 (neutral). MACD shows bullish momentum with histogram at 0.6986. Bollinger range: 111.31 – 124.37 SAR.
Support & Resistance Levels
Key support at SAR 111.31. Resistance at SAR 143.5. A break below support could push the stock toward SAR 107.97, while a breakout above resistance opens the path to SAR 147.81.
Volume Analysis
Session volume 51,458 shares is below the 30-day average (52,481 shares). Lower volume may indicate a wait-and-see market stance.
Fundamental Factors
P/E ratio at 17.4x. Dividend yield around 2.9%, attractive for income investors. Market cap SAR 8,344,000,000.0.
Risk Factors
Technical indicators sit in neutral territory (RSI 48, debt-to-equity 0.0203).
Recommendation
Based on current technical and fundamental data for Jamjoom Pharma. Monitor support at SAR 111.31 and resistance at SAR 143.5 for entry and exit points.
Financial Fundamentals
Price Data
Price Chart - Jamjoom Pharma
4015Technical Analysis
Moving Averages
Momentum Indicators
Bollinger Bands
Within BandTrend Strength (ADX)
Moderate TrendFinancial Summary
Valuation
- Market Cap
- 8.34B
- P/E Ratio
- 17.40
- P/B Ratio
- 4.60
- EPS (Earnings/Share)
- 6.87
Profitability
- Revenue
- 1.59B
- Net Income
- 484.13M
- Return on Equity (ROE)
- +27.80%
- Shares Outstanding
- 70.00M
Balance Sheet
- Total Assets
- 2.05B
- Total Debt
- 37.15M
- Debt/Equity
- 0.02
- Free Float %
- +34.3%
Dividends & Margins
- Dividend Yield
- +3.59%
- Dividend/Share
- 4.20
- Book Value
- 25.91
Financial data extracted from published quarterly reports. All values in SAR unless otherwise stated.
Historical Financial Data
5 years| Year | Revenue | Net Income | Total Assets | Total Debt | EPS |
|---|---|---|---|---|---|
| 2025 | 1.50B +13.8% | 463.80M +30.1% | 2.05B +15.5% | 16.43M +684.5% | 6.63 +30.3% |
| 2024 | 1.32B +19.8% | 356.52M +21.9% | 1.77B +7.1% | 2.09M -12.8% | 5.09 +21.8% |
| 2023 | 1.10B +20.1% | 292.40M +70.7% | 1.65B +17.5% | 2.40M -8.9% | 4.18 +70.6% |
| 2022 | 916.67M | 171.31M | 1.41B | 2.64M | 2.45 |
| 2021 | — | — | — | — | — |
Historical data sourced from Yahoo Finance and may differ from official audited financial reports.
Price Forecast
These forecasts are based on technical analysis and AI and do not constitute investment advice. Past performance does not guarantee future results.
News & Events
No news currently available for Jamjoom Pharma
Dividend History
Dividend data from Tadawul records. All amounts in SAR. Estimated yield calculated based on year-end price.
Ownership Structure
Data source: Yahoo FinanceLast updated: 2026-11-17
Risk Assessment
Risk Factors
Average True Range 2.3% of stock price
Trading volume near or above average
P/E ratio 17.4
Debt-to-equity ratio 0.02
ADX indicator at 22
Moderate risk factors with some sector pressures
This assessment is automated based on quantitative data and does not constitute investment advice. Please consult a licensed financial advisor before making investment decisions.
FAQ
1 What is Jamjoom Pharma stock price today?
Jamjoom Pharma (4015) stock price today is 119.20 SAR, gaining by +1.79% compared to the previous session close. The 52-week price range is between 112.20 SAR and 161.07 SAR.
2 What is Jamjoom Pharma stock valuation?
The automated analysis signal for Jamjoom Pharma is "Hold" with 50% confidence. The P/E ratio is 17.4. The P/B ratio is 4.60.
3 Is Jamjoom Pharma Shariah-compliant?
Yes, Jamjoom Pharma (4015) is Shariah-compliant according to the latest lists approved by relevant Shariah authorities.
4 What are Jamjoom Pharma dividend distributions?
Jamjoom Pharma has a dividend yield of 3.59%, with an estimated annual dividend of 4.20 SAR per share.
5 What is Jamjoom Pharma weekly performance?
Jamjoom Pharma performance over different time periods: weekly change +5.67%, monthly -4.26%, and year-to-date -14.59%. The stock is currently trading with a volume of 51,458 shares.
6 What is the target level for Jamjoom Pharma?
According to automated analysis for Jamjoom Pharma: Short-term target (1-2 weeks): 122.78 SAR. Medium-term target (1-3 months): 128.74 SAR. Support level: 111.31 SAR. Resistance level: 143.50 SAR. Note: These are automated analytical levels and do not constitute investment advice.
Disclaimer
The information provided on this page is for educational and analytical purposes only and does not constitute investment advice or a recommendation to buy or sell. Past performance does not guarantee future results. All investments involve risk including loss of capital. Please consult a licensed financial advisor before making any investment decisions.
Automated analysis relies on historical data and technical indicators and may not reflect future market conditions.